Stay updated with breaking news from Surrogate Measures. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Drugs to treat serious or life-threatening conditions can receive accelerated FDA approval, but may expose patients to increased safety risks and reduced efficacy
Share this article Share this article ResearchAndMarkets.com's offering. Designing for Recruitment and Retention in Rare Disease Studies report takes a deep dive into two areas impacting the success of these studies: recruitment and retention. Given the importance of each rare disease patient, these activities are time-intensive and resource-heavy. We asked 125 respondents involved in these activities about the challenges they face, methods and support services used, and their perspectives and practices regarding patient-friendly alternatives to the clinical setting. An area of a clinical st...